Meanwhile, we deeply and comprehensively analyzed the role pattern of MX2 in ccRCC, and validated its influence on sunitinib resistance through in vitro experiments, making it a potential clinical target. Here, MX2 is linked to nonpapillary renal cell carcinoma.